House Dust Mite Allergy-Pipeline Review, H1 2015

Products Id :- GMDHC6200IDB
|
Pages: 54
|
January 2015
|
Region: Global
|

Request for Sample Report

Executive Summary

Summary

Global Markets Direct's, 'House Dust Mite Allergy-Pipeline Review, H1 2015', provides an overview of the House Dust Mite Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for House Dust Mite Allergy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the House Dust Mite Allergy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

House Dust Mite Allergy Overview 6

Therapeutics Development 7

Pipeline Products for House Dust Mite Allergy-Overview 7

Pipeline Products for House Dust Mite Allergy-Comparative Analysis 8

House Dust Mite Allergy-Therapeutics under Development by Companies 9

House Dust Mite Allergy-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

House Dust Mite Allergy-Products under Development by Companies 13

House Dust Mite Allergy-Companies Involved in Therapeutics Development 14

ALK-Abello A/S 14

Anergis SA 15

Biomay AG 16

Circassia Pharmaceuticals plc 17

DBV Technologies S.A. 18

HAL Allergy BV 19

Stallergenes S.A. 20

House Dust Mite Allergy-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

AllerDM-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

allergenic pollen extract of timothy-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

BM-35-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

House Dust Mite-SPIRE-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

MK-8237-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

PL-103-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

S-524101-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Viaskin House Dust Mite-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

House Dust Mite Allergy-Recent Pipeline Updates 39

House Dust Mite Allergy-Dormant Projects 43

House Dust Mite Allergy-Discontinued Products 44

House Dust Mite Allergy-Product Development Milestones 45

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

House Dust Mite Allergy-Pipeline Review, H1 2015

Wish to Know more

download

For Further Enquiry

apply for job

Know how We Roll

Engage with Us